medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 3

<< Back Next >>

Medicina & Laboratorio 2021; 25 (3)

Immune complex-mediated rapidly progressive glomerulonephritis (type II). Literature review

Nieto-Ríos JF, Giraldo-Serna MB, García-Prada CA, Lotero-Cadavid AF, Serna-Higuita LM, Arias LF

Language: Spanish
References: 51
Page: 569-580
PDF size: 470.00 Kb.


ABSTRACT

Rapidly progressive immune complex-mediated glomerulonephritis (RPGNMN II) is a clinical syndrome characterized by severe deterioration of renal function associated with hematuria, edema, and oliguria. It is histologically characterized as a crescentic glomerulonephritis, with the presence of granular deposits on immunofluorescence. Although it is a rare condition, it is a potentially serious disease that may progress to chronic renal disease, therefore its early identification is essential. Here we present a review of this form of glomerulonephritis, with emphasis on its etiology and the currently available therapeutic options.


REFERENCES

  1. Ramos JM, Medina AB, Fernández MP. Glomerulonefritisagudas y rápidamente progresivas.Medicine 2019;12:4717-4724. https://doi.org/10.1016/j.med.2019.05.029.

  2. Couser WG. Rapidly progressive glomerulonephritis:classification, pathogeneticmechanisms, and therapy. Am J Kidney Dis1988;11:449-464. https://doi.org/10.1016/s0272-6386(88)80079-9.

  3. Parmar MS, Bashir K. Crescentric Glomerulonephritis.StatPearls. Treasure Island (FL): Stat-Pearls Publishing; 2021. Acceso 15 de abril de2020. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK430727/.

  4. Sethi S, Haas M, Markowitz GS, D'Agati VD,Rennke HG, Jennette JC, et al. Mayo Clinic/Renal Pathology Society consensus report onpathologic classification, diagnosis, and reportingof GN. J Am Soc Nephrol 2016;27:1278-1287. https://doi.org/10.1681/asn.2015060612.

  5. Appel G, Radhakrishnan J. Enfermedadesglomerulares y síndromes nefróticos. In: GoldmanL, Schaefer A, eds. Tratado de Medicina Interna.Ámsterdam, Países Bajos: Elsevier; 2016.p. 783-793.

  6. Johnson R, Feehally J, Floege J, Tonelli M. Introductionto glomerular disease : Clinical presentations. Comprehensive Clinical Nephrology.Ámsterdam, Países Bajos: Elsevier; 2019. p.184-198.

  7. Praga-Terente M. Nefropatías glomerularesprimarias. In: Rozman-Borstnar C, Cardellach-López F, eds. Medicina Interna. España: ACMElibreria ciencia medicina; 2020. p. 845-854.

  8. Baldwin DS, Neugarten J, Feiner HD, GluckM, Spinowitz B. The existence of a protractedcourse in crescentic glomerulonephritis. KidneyInt 1987;31:790-794. https://doi.org/10.1038/ki.1987.67.

  9. Moroni G, Ponticelli C. Rapidly progressivecrescentic glomerulonephritis: Early treatmentis a must. Autoimmun Rev 2014;13:723-729.https://doi.org/10.1016/j.autrev.2014.02.007.

  10. Jennette JC. Rapidly progressive crescentic glomerulonephritis.Kidney Int 2003;63:1164-1177.https://doi.org/10.1046/j.1523-1755.2003.00843.x.

  11. Choudhury TA, Singh RG, Singh S, Singh TB,Rathore SS. Clinicopathologic spectrum of crescenticglomerulonephritis: a hospital-based study.Saudi J Kidney Dis Transpl 2014;25:689-696.https://doi.org/10.4103/1319-2442.132241.

  12. Kidney Disease: Improving Global Outcomes(KDIGO). Chapter 10: ImmunoglobulinA nephropathy. Kidney Int Suppl (2011)2012;2:209-217. https://doi.org/10.1038/kisup.2012.23.

  13. Aguiar A, Alvarer P, Paz-Wasiuchnik V, AbibA, Ciliberti E, Moretti L, et al. Glomerulonefritisrápidamente progresiva en ancianos. Medicina(Buenos Aires) 2013;73:148-152.

  14. Wu T, Peng J, Meng T, Liu Q, Ao X, Lin W, etal. Clinicopathological features and prognosticanalysis of 49 cases with crescentic glomerulonephritis.Exp Ther Med 2019;18:3984-3990.https://doi.org/10.3892/etm.2019.8023.

  15. Chen M, Cui Z, Zhao MH. ANCA-associatedvasculitis and anti-GBM disease: the experiencein China. Nephrol Dial Transplant2010;25:2062-2065. https://doi.org/10.1093/ndt/gfq134.

  16. Bonsib SM. Glomerular basement membranediscontinuities. Scanning electron microscopicstudy of acellular glomeruli. Am J Pathol1985;119:357-360.

  17. Atkins RC, Nikolic-Paterson DJ, Song Q, LanHY. Modulators of crescentic glomerulonephritis.J Am Soc Nephrol 1996;7:2271-2278.https://doi.org/10.1681/asn.V7112271.

  18. Praga M, Gutierrez-Millet V, Navas JJ, RuilopeLM, Morales JM, Alcazar JM, et al. Acuteworsening of renal function during episodesof macroscopic hematuria in IgA nephropathy.Kidney Int 1985;28:69-74. https://doi.org/10.1038/ki.1985.120.

  19. Bennett WM, Kincaid-Smith P. Macroscopichematuria in mesangial IgA nephropathy:correlation with glomerular crescents and renaldysfunction. Kidney Int 1983;23:393-400.https://doi.org/10.1038/ki.1983.32.

  20. Arimura Y, Muso E, Fujimoto S, HasegawaM, Kaname S, Usui J, et al. Evidence-basedclinical practice guidelines for rapidly progressiveglomerulonephritis 2014. Clin Exp Nephrol2016;20:322-341. https://doi.org/10.1007/s10157-015-1218-8.

  21. Bruns FJ, Adler S, Fraley DS, Segel DP. Longtermfollow-up of aggressively treated idiopathicrapidly progressive glomerulonephritis.Am J Med 1989;86:400-406. https://doi.org/10.1016/0002-9343(89)90336-7.

  22. Bagga A, Menon S. Rapidly progressive glomerulonephritis.In: Geary D, Schaefer F, eds.Comprehensive Pediatric Nephrology Mosby.1st ed; 2008. p. 319-328.

  23. Rodríguez-Iturbe B. Epidemic poststreptococcalglomerulonephritis. Kidney Int 1984;25:129-136. https://doi.org/10.1038/ki.1984.19.

  24. Nissenson AR, Baraff LJ, Fine RN, KnutsonDW. Poststreptococcal acute glomerulonephritis:fact and controversy. Ann Intern Med1979;91:76-86. https://doi.org/10.7326/0003-4819-91-1-76.

  25. Blyth CC, Robertson PW, Rosenberg AR.Post-streptococcal glomerulonephritis in Sydney:a 16-year retrospective review. J PaediatrChild Health 2007;43:446-450. https://doi.org/10.1111/j.1440-1754.2007.01109.x.

  26. Sanjad S, Tolaymat A, Whitworth J, LevinS. Acute glomerulonephritis in children: a reviewof 153 cases. South Med J 1977;70:1202-1206. https://doi.org/10.1097/00007611-197710000-00015.

  27. Sagel I, Treser G, Ty A, Yoshizawa N, KleinbergerH, Yuceoglu AM, et al. Occurrenceand nature of glomerular lesions after groupA streptococci infections in children. AnnIntern Med 1973;79:492-499. https://doi.org/10.7326/0003-4819-79-4-492.

  28. Gutiérrez E, González E, Hernández E, MoralesE, Martínez MA, Usera G, et al. Factorsthat determine an incomplete recoveryof renal function in macrohematuria-inducedacute renal failure of IgA nephropathy. Clin JAm Soc Nephrol 2007;2:51-57. https://doi.org/10.2215/cjn.02670706.

  29. Peru H, Soylemezoglu O, Bakkaloglu SA,Elmas S, Bozkaya D, Elmaci AM, et al. HenochSchonlein purpura in childhood: clinicalanalysis of 254 cases over a 3-year period. ClinRheumatol 2008;27:1087-1092. https://doi.org/10.1007/s10067-008-0868-2.

  30. Trapani S, Micheli A, Grisolia F, Resti M,Chiappini E, Falcini F, et al. Henoch Schonleinpurpura in childhood: epidemiological and clinicalanalysis of 150 cases over a 5-year periodand review of literature. Semin Arthritis Rheum2005;35:143-153. https://doi.org/10.1016/j.semarthrit.2005.08.007.

  31. Peeters V, De Raeve L. Blistering eruptions inHenoch-Schönlein syndrome: more commonthan assumed. Eur J Pediatr 2018;177:475-476.https://doi.org/10.1007/s00431-017-2990-0.

  32. Wu CS, Tung SY. Henoch-Schönlein purpuracomplicated by upper gastrointestinal bleedingwith an unusual endoscopic picture. J ClinGastroenterol 1994;19:128-131. https://doi.org/10.1097/00004836-199409000-00011.

  33. Nathan K, Gunasekaran TS, Berman JH. Recurrentgastrointestinal Henoch-Schönlein purpura.J Clin Gastroenterol 1999;29:86-89. https://doi.org/10.1097/00004836-199907000-00022.

  34. Johnson EF, Lehman JS, Wetter DA, LohseCM, Tollefson MM. Henoch-Schönlein purpuraand systemic disease in children: retrospectivestudy of clinical findings, histopathology anddirect immunofluorescence in 34 paediatricpatients. Br J Dermatol 2015;172:1358-1363.https://doi.org/10.1111/bjd.13472.

  35. Greenhall GH, Salama AD. What is new in themanagement of rapidly progressive glomerulonephritis?Clin Kidney J 2015;8:143-150.https://doi.org/10.1093/ckj/sfv008.

  36. Rovin BH, Furie R, Latinis K, Looney RJ, FervenzaFC, Sanchez-Guerrero J, et al. Efficacyand safety of rituximab in patients with activeproliferative lupus nephritis: the Lupus NephritisAssessment with Rituximab study. ArthritisRheum 2012;64:1215-1226. https://doi.org/10.1002/art.34359.

  37. Condon MB, Ashby D, Pepper RJ, CookHT, Levy JB, Griffith M, et al. Prospectiveobservational single-centre cohort study toevaluate the effectiveness of treating lupusnephritis with rituximab and mycophenolatemofetil but no oral steroids. Ann Rheum Dis2013;72:1280-1286. https://doi.org/10.1136/annrheumdis-2012-202844.

  38. Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ,Sanna G, et al. Rituximab therapy in lupusnephritis: current clinical evidence. Clin RevAllergy Immunol 2011;40:159-169. https://doi.org/10.1007/s12016-010-8205-3.

  39. Tsanian M, Solov'ev SK, Torgashina AV,Aleksandrova EN, Radenska-Lopovok SG,Nikolaeva EV, et al. [Long-term follow-up ofpatients with refractory systemic lupus erythematosusduring rituximab treatment]. Ter Arkh2014;86:40-49.

  40. Lafayette RA, Canetta PA, Rovin BH, AppelGB, Novak J, Nath KA, et al. A randomized,controlled trial of rituximab in IgA nephropathywith proteinuria and renal dysfunction. J AmSoc Nephrol 2017;28:1306-1313. https://doi.org/10.1681/asn.2016060640.

  41. El-Husseini A, Ahmed A, Sabucedo A, FabuloE. Refractory Henoch-Schönlein purpura:atypical aetiology and management. J RenCare 2013;39:77-81. https://doi.org/10.1111/j.1755-6686.2013.12007.x.

  42. Fenoglio R, Naretto C, Basolo B, QuattrocchioG, Ferro M, Mesiano P, et al. Rituximabtherapy for IgA-vasculitis with nephritis: a caseseries and review of the literature. ImmunolRes 2017;65:186-192. https://doi.org/10.1007/s12026-016-8827-5.

  43. Chancharoenthana W, Townamchai N, LeelahavanichkulA, Wattanatorn S, KanjanabuchT, Avihingsanon Y, et al. Rituximab for recurrentIgA nephropathy in kidney transplantation:A report of three cases and proposed mechanisms.Nephrology (Carlton) 2017;22:65-71.https://doi.org/10.1111/nep.12722.

  44. Chen X, Chen N. Plasma exchange in thetreatment of rapidly progressive glomerulonephritis.Contrib Nephrol 2013;181:240-247.https://doi.org/10.1159/000348632.

  45. Appel GB, Waldman M. The IgA nephropathytreatment dilemma. Kidney Int 2006;69:1939-1944. https://doi.org/10.1038/sj.ki.5000434.

  46. Barratt J, Feehally J. Treatment of IgA nephropathy.Kidney Int 2006;69:1934-1938. https://doi.org/10.1038/sj.ki.5000419.

  47. Saulsbury FT. Henoch-Schönlein purpurain children. Report of 100 patients andreview of the literature. Medicine (Baltimore)1999;78:395-409. https://doi.org/10.1097/00005792-199911000-00005.

  48. Cheigh JS, Kim H, Stenzel KH, Tapia L, SullivanJF, Stubenbord W, et al. Systemic lupuserythematosus in patients with end-stage renaldisease: long-term follow-up on the prognosisof patients and the evolution of lupus activity.Am J Kidney Dis 1990;16:189-195. https://doi.org/10.1016/s0272-6386(12)81017-1.

  49. Chagnac A, Kiberd BA, Fariñas MC, StroberS, Sibley RK, Hoppe R, et al. Outcome ofthe acute glomerular injury in proliferative lupusnephritis. J Clin Invest 1989;84:922-930.https://doi.org/10.1172/jci114254.

  50. Raff A, Hebert T, Pullman J, Coco M. Crescenticpost-streptococcal glomerulonephritis withnephrotic syndrome in the adult: is aggressivetherapy warranted? Clin Nephrol 2005;63:375-380. https://doi.org/10.5414/cnp63375.

  51. Roy S 3rd, Murphy WM, Arant BS Jr. Poststreptococcalcrescenteric glomerulonephritis inchildren: comparison of quintuple therapy versussupportive care. J Pediatr 1981;98:403-410.https://doi.org/10.1016/s0022-3476(81)80703-2.




2020     |     www.medigraphic.com